BR9713522A - Método de uso de inibidores da cicloxigenase-2 como agentes antiangiogênicos. - Google Patents

Método de uso de inibidores da cicloxigenase-2 como agentes antiangiogênicos.

Info

Publication number
BR9713522A
BR9713522A BR9713522A BR9713522A BR9713522A BR 9713522 A BR9713522 A BR 9713522A BR 9713522 A BR9713522 A BR 9713522A BR 9713522 A BR9713522 A BR 9713522A BR 9713522 A BR9713522 A BR 9713522A
Authority
BR
Brazil
Prior art keywords
cyclooxygenase
inhibitors
antiangiogenic agents
antiangiogenic
agents
Prior art date
Application number
BR9713522A
Other languages
English (en)
Portuguese (pt)
Inventor
Jaime L Masferrer
Amiran Raz
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of BR9713522A publication Critical patent/BR9713522A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9713522A 1996-11-19 1997-11-19 Método de uso de inibidores da cicloxigenase-2 como agentes antiangiogênicos. BR9713522A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3140496P 1996-11-19 1996-11-19
PCT/US1997/021489 WO1998022101A2 (en) 1996-11-19 1997-11-19 Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents

Publications (1)

Publication Number Publication Date
BR9713522A true BR9713522A (pt) 2000-03-21

Family

ID=21859277

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9713522A BR9713522A (pt) 1996-11-19 1997-11-19 Método de uso de inibidores da cicloxigenase-2 como agentes antiangiogênicos.

Country Status (19)

Country Link
EP (1) EP0941080A2 (sk)
JP (1) JP2001505564A (sk)
KR (1) KR20000053362A (sk)
CN (1) CN1247470A (sk)
AU (1) AU730211B2 (sk)
BR (1) BR9713522A (sk)
CA (1) CA2270469C (sk)
CZ (1) CZ176899A3 (sk)
ID (1) ID21979A (sk)
IL (1) IL129604A (sk)
NO (1) NO992309L (sk)
NZ (1) NZ335853A (sk)
PL (2) PL194717B1 (sk)
RO (1) RO118566B1 (sk)
RU (1) RU2268716C2 (sk)
SK (1) SK59999A3 (sk)
TR (1) TR199901703T2 (sk)
UA (1) UA70294C2 (sk)
WO (1) WO1998022101A2 (sk)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515014B2 (en) 1995-06-02 2003-02-04 G. D. Searle & Co. Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6512121B2 (en) 1998-09-14 2003-01-28 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6887893B1 (en) 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
JP2002533387A (ja) * 1998-12-23 2002-10-08 ジー．ディー．サール ＆ カンパニー 腫瘍治療の複合療法としてインテグリン拮抗物質と一つ以上の抗腫瘍剤を使用する方法
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
WO2000053149A2 (en) * 1999-03-10 2000-09-14 G.D. Searle & Co. Method and composition for administering a cyclooxygenase-2 inhibitor
AU775305B2 (en) * 1999-07-29 2004-07-29 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamide and platin compound
AU6469401A (en) 2000-05-19 2001-11-26 Serono Reproductive Biology In Pharmaceutically active compounds and methods of use
WO2002039958A2 (en) 2000-11-03 2002-05-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
KR100686537B1 (ko) * 2001-12-28 2007-02-27 씨제이 주식회사 사이클로옥시게나제-2 의 저해제로서 선택성이 뛰어난디아릴 1,2,4-트리아졸 유도체
EP1530475A2 (en) * 2002-07-17 2005-05-18 Warner-Lambert Company LLC Pharmaceutical compositions comprising an allosteric carboxylic inhibitor of matrix metalloproteinase-13 and a selective inhibitor of cyclooxygenase-2
KR100484525B1 (ko) * 2002-10-15 2005-04-20 씨제이 주식회사 이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
AT504159A1 (de) * 2006-08-16 2008-03-15 Marlyn Nutraceuticals Inc Verwendung von proteasen
RU2475257C1 (ru) * 2011-06-22 2013-02-20 Людмила Николаевна Третьяк Средство для повышения адаптируемости организма к экстремальным условиям
GB2496135B (en) * 2011-11-01 2015-03-18 Valirx Plc Inhibitors of the interaction between a Src family kinase and an androgen receptor or estradiol receptor for treatment of endometriosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6027694A (en) * 1993-01-15 1994-08-15 G.D. Searle & Co. Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
PL180717B1 (pl) * 1993-11-30 2001-03-30 Searle & Co N o w e 1 -[4-(aminosulfonylo)fenylo]pirazolilobenzenosulfonamidy do leczenia stanów zapalnych PL PL PL PL PL PL PL
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
EP0799218B1 (en) * 1994-12-21 2003-02-19 Merck Frosst Canada & Co. Diaryl-2-(5h)-furanones as cox-2 inhibitors
US5691374A (en) * 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors

Also Published As

Publication number Publication date
TR199901703T2 (xx) 2000-07-21
IL129604A (en) 2004-08-31
PL194717B1 (pl) 2007-06-29
WO1998022101A2 (en) 1998-05-28
CA2270469A1 (en) 1998-05-28
SK59999A3 (en) 2000-01-18
RO118566B1 (ro) 2003-07-30
CZ176899A3 (cs) 1999-10-13
EP0941080A2 (en) 1999-09-15
NZ335853A (en) 2002-02-01
WO1998022101A3 (en) 1998-06-25
CN1247470A (zh) 2000-03-15
CA2270469C (en) 2007-04-10
NO992309D0 (no) 1999-05-12
PL191793B1 (pl) 2006-07-31
ID21979A (id) 1999-08-19
NO992309L (no) 1999-05-12
UA70294C2 (en) 2004-10-15
JP2001505564A (ja) 2001-04-24
PL333370A1 (en) 1999-12-06
AU730211B2 (en) 2001-03-01
IL129604A0 (en) 2000-02-29
KR20000053362A (ko) 2000-08-25
RU2268716C2 (ru) 2006-01-27
AU7298298A (en) 1998-06-10

Similar Documents

Publication Publication Date Title
BR9713522A (pt) Método de uso de inibidores da cicloxigenase-2 como agentes antiangiogênicos.
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
ATE301457T1 (de) Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
DE69725484D1 (de) Vorrichtung zur Behandlung von Harninkontinenz
ES2172657T3 (es) Inhibidores de trombina.
NO974680D0 (no) Anvendelse av midler som frigir nitrogenholdig oksyd for behandling av impotens
BR9916567A (pt) Combinações de inibidores do transporte ácido dabile ileal e derivados do ácido nicotìnico paraindicações cardiovasculares
EE9700267A (et) a1L- agonistide kasutamine uriiniinkontinentsuse raviks
DE69608804D1 (de) Di- und trivalente kleine moleküle als selektininhibitoren
EP0793489A4 (en) AGENTS FOR TREATING SKIN DISEASES
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
GB9804886D0 (en) Therapeutic combination
MX9805290A (es) Utilizacion de inhibidores de la actividad del acido retinoico para tratar las pieles sensibles y/o los daños agudos inducidos por las radiaciones ultravioleta.
WO1998005291A3 (en) Method for treating mental retardation
NO990450D0 (no) Behandling av sinnslidelser
ES2149448T3 (es) Agentes terapeuticos y analiticos.
MXPA02004699A (es) Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco.
IL139144A0 (en) Mycobacterial inhibitors
EE9700350A (et) COMT-inhibiitorite uus kasutamine ja diabeetiliste vaskulaarsete häirete ärahoidmise meetod
NO963989L (no) Hypokolesterolemiske-, antiatherosklerotiske- og hypotriglyceridemiske mercaptoacetylamidderivater
ATA93695A (de) Mittel zur behandlung von strahlenschäden
ATE202089T1 (de) Chinolonderivat zur behandlung der harnincontinenz
BR0112460A (pt) Método para tratamento de sépsis
MY140504A (en) Statin-mmp inhibitor combinations

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ART. 8O COMBINADO COM ART. 13 DA LPI ).

B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 31/00, A61K 31/45, A61P 35/00, A61P 15/00

Ipc: A61K 31/00 (2007.10), A61K 31/45 (2007.10), A61K 3